Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 101, Issue , 2015, Pages 15-21

  Smesny, Stefan ^a   Milleit, Berko ^a,f   Schaefer, Miriam R ^b,c   Hipler, Uta Christina ^a   Milleit, Christine ^a   Wiegand, Cornelia ^a   Hesse, Jana ^a   Klier, Claudia M ^b   Holub, Magdalena ^b   Holzer, Ingrid ^b   Berk, Michael ^c,d,e   McGorry, Patrick D ^c   Sauer, Heinrich ^a   Paul Amminger, G ^b,c  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f Thueringen Kliniken GmbH   (Germany)

Author keywords

At risk mental state; Follow up; Longitudinal; Omega 3 fatty acids; Oxidative stress; Schizophrenia

Indexed keywords

ALPHA TOCOPHEROL; DELTA TOCOPHEROL; DOCOSAHEXAENOIC ACID; GAMMA TOCOPHEROL; GLUTATHIONE; GLUTATHIONE DISULFIDE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; SATURATED FATTY ACID; ANTIOXIDANT; FATTY ACID;

ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ANTIOXIDANT DEFENSE SYSTEM; ARTICLE; BIOLOGICAL ACTIVITY; CELL MEMBRANE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CAPSULE; FEMALE; HELP SEEKING BEHAVIOR; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; TREND STUDY; ULTRA-HIGH RISK PATIENT; VITAMIN BLOOD LEVEL; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANTIOXIDANTS; CROSS-SECTIONAL STUDIES; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; VITAMIN E; YOUNG ADULT;

EID: 84941880094     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.07.001     Document Type: Article

References (64)

1. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 2006, 18:119-131. Abingdon, England.
2. Boskovic M., Vovk T., Kores Plesnicar B., Grabnar I. Oxidative stress in schizophrenia. Curr. Neuropharmacol. 2011, 9:301-312.
3. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal. 2011, 15:2011-2035.
4. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
5. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singap. 2009, 38. 396-396.
6. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74:400-409.
7. Parellada M., Moreno C., Mac-Dowell K., Leza J.C., Giraldez M., Bailon C., Castro C., Miranda-Azpiazu P., Fraguas D., Arango C. Plasma antioxidant capacity is reduced in Asperger syndrome. J. Psychiatr. Res. 2012, 46:394-401.
8. Villagonzalo K.A., Dodd S., Dean O., Gray K., Tonge B., Berk M. Oxidative pathways as a drug target for the treatment of autism. Expert Opin. Ther. Targets 2010, 14:1301-1310.
9. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
10. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:676-692.
11. Berk M., Conus P., Kapczinski F., Andreazza A.C., Yucel M., Wood S.J., Pantelis C., Malhi G.S., Dodd S., Bechdolf A., Amminger G.P., Hickie I.B., McGorry P.D. From neuroprogression to neuroprotection: implications for clinical care. Med. J. Aust. 2010, 193:S36-S40.
12. Akiibinu M.O., Ogundahunsi O.A., Ogunyemi E.O. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res. Notes 2012, 5:169.
13. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003, 53:56-64.
14. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1164-1169.
15. Dadheech G., Mishra S., Gautam S., Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J. Psychiatry 2008, 50:16-20.
16. Owe-Larsson B., Ekdahl K., Edbom T., Osby U., Karlsson H., Lundberg C., Lundberg M. Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1117-1121.
17. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 2008, 79:346-351.
18. Kulak A., Steullet P., Cabungcal J.H., Werge T., Ingason A., Cuenod M., Do K.Q. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid. Redox Signal. 2013, 18:1428-1443.
19. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12:3721-3728.
20. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis. Markers 2006, 22:83-93.
21. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
22. Mico J.A., Rojas-Corrales M.O., Gibert-Rahola J., Parellada M., Moreno D., Fraguas D., Graell M., Gil J., Irazusta J., Castro-Fornieles J., Soutullo C., Arango C., Otero S., Navarro A., Baeza I., Martinez-Cengotitabengoa M., Gonzalez-Pinto A. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 2011, 11:26.
23. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 2014, 53:112-124.
24. Ciobica A., Padurariu M., Dobrin I., Stefanescu C., Dobrin R. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr. Danub. 2014, 23:237-245.
25. Morris G., Anderson G., Dean O., Berk M., Galecki P., Martin-Subero M., Maes M. The glutathione system: a new drug target in neuroimmune disorders. Mol. Neurobiol. 2014, Apr 22. [Epub ahead of print].
26. Meydani M. Vitamin E. Lancet 1995, 345:170-175.
27. Packer L., Kagan V.E. Vitamin E: the antioxidant harvesting center of membranes and lipoproteins. Vitamin E in Health and Disease 1993, 179-192. Marcel Dekker, Inc., Wanshington D.C. L. Packer, J. Fuchs (Eds.).
28. Traber M.G., Sies H. Vitamin E in humans: demand and delivery. Ann. Rev. Nutr. 1995, 16:321-347.
29. Bentsen H., Solberg D.K., Refsum H., Gran J.M., Bohmer T., Torjesen P.A., Halvorsen O., Lingjaerde O. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol. Psychiatry 2011, 70:97-105.
30. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58:1-10.
31. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:463-493.
32. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009, 19:220-230.
33. Genius J., Geiger J., Dolzer A.L., Benninghoff J., Giegling I., Hartmann A.M., Moller H.J., Rujescu D. Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. PLoS One 2013, 8:e59395.
34. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43:674-679.
35. Martinez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Mico J.A., Fernandez M., Echevarria E., Sanjuan J., Elorza J., Gonzalez-Pinto A. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr. Res. 2012, 137:66-72.
36. Marchbanks R.M., Ryan M., Day I.N., Owen M., McGuffin P., Whatley S.A. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr. Res. 2003, 65:33-38.
37. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., Matthey M.L., Parnas J., Preisig M., Saraga M., Solida A., Timm S., Wang A.G., Werge T., Cuenod M., Do K.Q. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 2006, 79:586-592.
38. Gysin R., Kraftsik R., Boulat O., Bovet P., Conus P., Comte-Krieger E., Polari A., Steullet P., Preisig M., Teichmann T., Cuenod M., Do K.Q. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid. Redox Signal. 2011, 15:2003-2010.
39. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., Tosic M., Werge T., Cuenod M., Do K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA 2007, 104:16621-16626.
40. Gonzalez-Pinto A., Martinez-Cengotitabengoa M., Arango C., Baeza I., Otero-Cuesta S., Graell-Berna M., Soutullo C., Leza J.C., Mico J.A. Antioxidant defense system and family environment in adolescents with family history of psychosis. BMC Psychiatry 2012, 12:200.
41. Emanuele E., Martinelli V., Abbiati V., Fusar-Poli P., Politi P. Biochemical markers of impending psychosis. Curr. Pharm. Des. 2012, 18:505-509.
42. Preti A., Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 2010, 123:30-36.
43. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
44. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
45. Smesny S., Milleit B., Hipler U.C., Milleit C., Schafer M.R., Klier C.M., Holub M., Holzer I., Berger G.E., Otto M., Nenadic I., Berk M., McGorry P.D., Sauer H., Amminger G.P. Omega-3 fatty acid supplementation changes intracellular phospholipase A activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol. Psychiatry 2014, 19:317-324.
46. Rosenson R.S., Stafforini D.M. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res. 2012, 53:1767-1782.
47. Andersen J.M., Myhre O., Fonnum F. Discussion of the role of the extracellular signal-regulated kinase-phospholipase A2 pathway in production of reactive oxygen species in Alzheimer[U+05F3]s disease. Neurochem. Res. 2003, 28:319-326.
48. Farooqui A.A., Ong W.Y., Horrocks L.A., Chen P., Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 2007, 56:443-471.
49. Law M.H., Cotton R.G., Berger G.E. The role of phospholipases A2 in schizophrenia. Mol. Psychiatry 2006, 11:547-556.
50. Valk E.E., Hornstra G. Relationship between vitamin E requirement and polyunsaturated fatty acid intake in man: a review. Int. J. Vitam. Nutr. Res. 2000, 70:31-42.
51. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., Woods S.W. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 2002, 159:863-865.
52. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996, 22:353-370.
53. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., Patton G.C., Jackson H.J. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 1998, 172:14-20.
54. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., Riecher-Rossler A., Klosterkotter J., Ruhrmann S., Schultze-Lutter F., Nordentoft M., Hickie I., McGuire P., Berk M., Chen E.Y., Keshavan M.S., Yung A.R. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70:1206-1212.
55. Diplock A.T., Xu G.L., Yeow C.L., Okikiola M. Relationship of tocopherol structure to biological activity, tissue uptake, and prostaglandin biosynthesis. Ann. N. Y. Acad. Sci. 1989, 570:72-84.
56. Fryer M.J. Potential of vitamin E as an antioxidant adjunct in Wilson[U+05F3]s disease. Med. Hypotheses 2009, 73:1029-1030.
57. Melchert H.-U., Pabel E. The tocopherol pattern in human serum is markedly influenced by intake of vitamin E drugs - results of the German National Health Surveys. J. Am. Oil Chem. Soc. 1998, 75:213-216.
58. Hoen W.P., Lijmer J.G., Duran M., Wanders R.J., van Beveren N.J., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013, 207:1-12.
59. Bentsen H., Osnes K., Refsum H., Solberg D.K., Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl. Psychiatry 2013, 3:e335.
60. Chowdari K.V., Bamne M.N., Nimgaonkar V.L. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid. Redox Signal. 2011, 15:2037-2045.
61. National Research Council (NRC) Recommended Dietary Allowances 1989, National Academy Press, Washington D.C. tenth ed.
62. WHO (Ed.) Food and Nutrition, Rome, 1994.
63. Empfehlungen für die Nährstoffzufuhr, fifth. ed., Umschau Verlag, Frankfurt, 1991.
64. Gassmann B., Kübler W. Ungesättigte Fettsäuren und Vitamin-E-Bedarf. Ernähr.-Umsch. 1996, 43:172-177.